Literature DB >> 23681269

Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions.

Keisuke Saito1, Soichiro Kimura, Tomoo Saga, Yoshi Misonoo, Sadako Yoshizawa, Yoshikiyo Akasaka, Toshiharu Ishii, Kazuyoshi Kuwano, Keizo Yamaguchi, Kazuhiro Tateda.   

Abstract

OBJECTIVES: Ventilator-associated pneumonia (VAP) is an important cause of morbidity and mortality in critical care settings. Acinetobacter has become a leading cause of VAP. In particular, the appearance and spread of multidrug-resistant Acinetobacter is of great concern. In this study, we examined the effect of the antioxidant procysteine on Acinetobacter murine pneumonia in hyperoxic conditions in order to simulate VAP.
METHODS: Acinetobacter was administered intranasally to BALB/c mice kept in hyperoxic conditions. At designated timepoints, bacterial number, cytokine production and histopathological findings in the lungs were examined. The effects of procysteine on survival rates, lung bacterial burdens and the phagocytic activities of alveolar macrophages were evaluated.
RESULTS: Drastic decreases in survival were observed when the infected mice were kept in hyperoxic conditions (P < 0.001). Significant differences in pulmonary bacterial number and neutrophil accumulation were observed between mice kept in hyperoxic or normoxic conditions on day 3. Although all mice infected with Acinetobacter spp. and kept in hyperoxic conditions died by day 3, procysteine treatment significantly improved survival (60% survival on day 7, P < 0.01). Procysteine treatment decreased the lung bacterial burden on days 2 and 3. Finally, improved uptake of FITC-labelled beads by alveolar macrophages from mice treated with procysteine and kept in hyperoxic conditions was noted.
CONCLUSIONS: These results suggest that hyperoxia increases mortality in mice with Acinetobacter pneumonia and that procysteine improves survival by increasing the phagocytic activity of alveolar macrophages in mice kept in hyperoxic conditions.

Entities:  

Keywords:  VAP; alveolar macrophages; phagocytic activity; ventilator-associated pneumonia

Mesh:

Substances:

Year:  2013        PMID: 23681269     DOI: 10.1093/jac/dkt192

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Relationship between hyperoxemia and ventilator associated pneumonia.

Authors:  Karim Jaffal; Sophie Six; Farid Zerimech; Saad Nseir
Journal:  Ann Transl Med       Date:  2017-11

2.  Ascorbic Acid Attenuates Hyperoxia-Compromised Host Defense against Pulmonary Bacterial Infection.

Authors:  Vivek S Patel; Vaishali Sampat; Michael Graham Espey; Ravikumar Sitapara; Haichao Wang; Xiaojing Yang; Charles R Ashby; Douglas D Thomas; Lin L Mantell
Journal:  Am J Respir Cell Mol Biol       Date:  2016-10       Impact factor: 6.914

Review 3.  Biological effects of the oxygen molecule in critically ill patients.

Authors:  Masaki Nakane
Journal:  J Intensive Care       Date:  2020-12-14

4.  Too much tolerance for hyperoxemia in mechanically ventilated patients with SARS-CoV-2 pneumonia? Report from an Italian intensive care unit.

Authors:  Elisa Damiani; Erika Casarotta; Andrea Carsetti; Giulia Mariotti; Sara Vannicola; Rachele Giorgetti; Roberta Domizi; Claudia Scorcella; Erica Adrario; Abele Donati
Journal:  Front Med (Lausanne)       Date:  2022-07-28

5.  Hyperoxemia as a risk factor for ventilator-associated pneumonia.

Authors:  Sophie Six; Karim Jaffal; Geoffrey Ledoux; Emmanuelle Jaillette; Frédéric Wallet; Saad Nseir
Journal:  Crit Care       Date:  2016-06-22       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.